Tuesday, July 21, 2009

Don't chase the triple


Yesterday, Human Genome Sciences (HGSI) more than tripled in value. Voume has increased by twice that. Thus far, today it is up another 10%. Don't chase performance. I know about the lupus trial. I know it's been upgraded. So does everybody. You missed your opportunity to buy this was days ago, before it took out its 52-week high. Don't rush into a money-losing biotech just because of momentum. Unless of course, you have a strong stomach.

No comments: